Bruce A. Chabner, MD

Advisor to the Education Council 

Dr. Bruce Chabner serves as the Allen Distinguished Investigator and Clinical Director Emeritus for the Massachusetts General Hospital Cancer Center.

His main fields of research focus on the biochemistry and pharmacology of folate antagonists, experimental therapeutics, and clinical trial design.

He has served as the Chief of Hematology and Oncology at the MGH from 1995 to 2007, the Clinical Director of the MGH Cancer Center from 1995 to 2010, and Associate Director of Clinical Science at Dana Farber/Harvard Cancer Center (2000-2010). Prior to accepting his position at MGH, he served in the US Public Health Service at the National Institutes of Health from 1971 to 1995 and held the position of Director of the Division of Cancer Treatment of the National Cancer Institute from 1982 to 1995, retiring as an Assistant Surgeon General in 1995.

Dr. Chabner received his BA, summa cum laude, from Yale College (1961) and an MD, cum laude, from Harvard Medical School (1965).

He has authored and edited the standard text, Principles and Practice of Cancer Chemotherapy and Biological Response Modifiers, now in its sixth edition, and the Harrison’s Manual of Oncology, now in its 2nd edition. Dr. Chabner has contributed to and served as editor of the Goodman and Gilman textbook of Pharmacology and has authored chapters for numerous other textbooks of internal medicine, hematology, oncology and pharmacology.

Over the years, Dr. Chabner has received awards including Phi Beta Kappa, Alpha Omega Alpha, the Public Health Service’s Distinguished Service Medal, the Karnofsky Award of the American Society for Clinical Oncology and the Bruce F. Cain Award for Drug Development of the American Association for Cancer Research. In 2006, he was the first recipient of the Bob Pinedo Award for Contributions to Improvement in the Care of Cancer Patients.

Dr. Chabner is founding editor-in-chief for The Oncologist and serves on the executive advisory boards for some of the industry’s leading innovators in drug development. In 2006, Dr. Chabner received a presidential appointment to the National Cancer Advisory Board at the National Cancer Institute and chaired the NCAB from (2010-2012). In 2020, he was selected to be the Inaugural speaker for the FDA series, “Icons of Oncology”’.Open configuration options